Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Next Previous
Search
Drug Profile

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease I stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Catheter infections

Most Recent Events

  • 25 Mar 2025 CorMedix submits an application for Orphan Drug Status for Parenteral nutrition to the US FDA
  • 27 Nov 2024 CorMedix initiates an expanded-access programme for Catheter infection (In prevention, In children, In adolescents, In adult, In the elderly) (NCT06707480)
  • 30 Oct 2024 CorMedix plans to initiate a clinical trial for Parenteral nutrition (In adults) in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top